Abstract:Repeated WAS for three consecutive days induced visceral allodynia, which was mediated through mast cells, IL-1, and IL-6 pathways. Inhibition of peripheral CRF signaling prevented but did not reverse this response, suggesting that peripheral CRF may be an essential trigger but may not contribute to the maintenance of repeated WAS-induced visceral allodynia.
“…As described before, LPS‐, repeated WAS‐, or CRF‐induced visceral allodynia and colonic hyperpermeability are considered to well simulate the pathophysiology of IBS, and we have previously demonstrated that CRF, TLR4, and proinflammatory cytokine signaling mediated these visceral changes …”
Section: Discussionmentioning
confidence: 99%
“…At the same time, NO inhibits the expression of proinflammatory cytokine genes in various immune cells and suppresses IL‐1β release from macrophages . Incidentally, the chemical mediators including cytokines released by degranulation of mast cells are known to contribute to stress‐induced visceral hypersensitivity and gut hyperpermeability, and NO inhibits the degranulation to improve gut permeability . Thus, losartan may inhibit proinflammatory cytokine signaling by facilitating NO production to improve visceral changes.…”
Section: Discussionmentioning
confidence: 99%
“…Next, the effects of losartan on repeated WAS model (1 hour daily for 3 consecutive days) were explored (Figure C). This model was shown to successfully and reproducibly induce visceral allodynia and colonic hyperpermeability in rats . The basal threshold was measured, and the vehicle or losartan was injected.…”
Section: Methodsmentioning
confidence: 99%
“…We have recently shown that LPS injection or repeated water avoidance stress (WAS) induced visceral allodynia and colonic hyperpermeability in rats (animal IBS models), and these changes were mediated via peripheral CRF, toll‐like receptor 4 (TLR4), and proinflammatory cytokine system . Moreover, peripheral injection of CRF mimicked these visceral changes via the TLR4 and cytokine‐dependent pathways .…”
Background: Lipopolysaccharide (LPS) or repeated water avoidance stress (WAS) induces visceral allodynia and colonic hyperpermeability via corticotropin-releasing factor (CRF) and proinflammatory cytokines, which is considered to be a rat irritable bowel syndrome (IBS) model. As losartan is known to inhibit proinflammatory cytokine release, we hypothesized that it improves these visceral changes.
Methods:The threshold of visceromotor response (VMR), that is, abdominal muscle contractions induced by colonic balloon distention was electrophysiologically measured in rats. Colonic permeability was determined in vivo by quantifying the absorbed Evans blue in colonic tissue for 15 minutes spectrophotometrically. Key Results: Lipopolysaccharide (1 mg kg −1 ) subcutaneously (s.c.) reduced the threshold of VMR and increased colonic permeability. Losartan (5-25 mg kg −1 s.c.) for 3 days inhibited these changes in a dose-dependent manner. Moreover, repeated WAS (1 hour daily for 3 days) or intraperitoneal injection of CRF (50 µg kg −1 ) induced the similar visceral changes as LPS, which were also eliminated by losartan. These effects by losartan in LPS model were reversed by GW9662 (a peroxisome proliferator-activated receptor-γ [PPAR-γ] antagonist), N G -nitro-L-arginine methyl ester (a nitric oxide [NO] synthesis inhibitor), or naloxone (an opioid receptor antagonist). Moreover, it also inhibited by sulpiride (a dopamine D 2 receptor antagonist) or domperidone (a peripheral dopamine D 2 antagonist).
Conclusion & Inferences:Losartan prevented visceral allodynia and colonic hyperpermeability in rat IBS models. These actions may be PPAR-γ-dependent and also mediated by the NO, opioid, and dopamine D 2 pathways. Losartan may be useful for IBS treatment.
K E Y W O R D Sangiotensin II type 1 receptor, gut barrier, irritable bowel syndrome, lipopolysaccharide, visceral sensation
“…As described before, LPS‐, repeated WAS‐, or CRF‐induced visceral allodynia and colonic hyperpermeability are considered to well simulate the pathophysiology of IBS, and we have previously demonstrated that CRF, TLR4, and proinflammatory cytokine signaling mediated these visceral changes …”
Section: Discussionmentioning
confidence: 99%
“…At the same time, NO inhibits the expression of proinflammatory cytokine genes in various immune cells and suppresses IL‐1β release from macrophages . Incidentally, the chemical mediators including cytokines released by degranulation of mast cells are known to contribute to stress‐induced visceral hypersensitivity and gut hyperpermeability, and NO inhibits the degranulation to improve gut permeability . Thus, losartan may inhibit proinflammatory cytokine signaling by facilitating NO production to improve visceral changes.…”
Section: Discussionmentioning
confidence: 99%
“…Next, the effects of losartan on repeated WAS model (1 hour daily for 3 consecutive days) were explored (Figure C). This model was shown to successfully and reproducibly induce visceral allodynia and colonic hyperpermeability in rats . The basal threshold was measured, and the vehicle or losartan was injected.…”
Section: Methodsmentioning
confidence: 99%
“…We have recently shown that LPS injection or repeated water avoidance stress (WAS) induced visceral allodynia and colonic hyperpermeability in rats (animal IBS models), and these changes were mediated via peripheral CRF, toll‐like receptor 4 (TLR4), and proinflammatory cytokine system . Moreover, peripheral injection of CRF mimicked these visceral changes via the TLR4 and cytokine‐dependent pathways .…”
Background: Lipopolysaccharide (LPS) or repeated water avoidance stress (WAS) induces visceral allodynia and colonic hyperpermeability via corticotropin-releasing factor (CRF) and proinflammatory cytokines, which is considered to be a rat irritable bowel syndrome (IBS) model. As losartan is known to inhibit proinflammatory cytokine release, we hypothesized that it improves these visceral changes.
Methods:The threshold of visceromotor response (VMR), that is, abdominal muscle contractions induced by colonic balloon distention was electrophysiologically measured in rats. Colonic permeability was determined in vivo by quantifying the absorbed Evans blue in colonic tissue for 15 minutes spectrophotometrically. Key Results: Lipopolysaccharide (1 mg kg −1 ) subcutaneously (s.c.) reduced the threshold of VMR and increased colonic permeability. Losartan (5-25 mg kg −1 s.c.) for 3 days inhibited these changes in a dose-dependent manner. Moreover, repeated WAS (1 hour daily for 3 days) or intraperitoneal injection of CRF (50 µg kg −1 ) induced the similar visceral changes as LPS, which were also eliminated by losartan. These effects by losartan in LPS model were reversed by GW9662 (a peroxisome proliferator-activated receptor-γ [PPAR-γ] antagonist), N G -nitro-L-arginine methyl ester (a nitric oxide [NO] synthesis inhibitor), or naloxone (an opioid receptor antagonist). Moreover, it also inhibited by sulpiride (a dopamine D 2 receptor antagonist) or domperidone (a peripheral dopamine D 2 antagonist).
Conclusion & Inferences:Losartan prevented visceral allodynia and colonic hyperpermeability in rat IBS models. These actions may be PPAR-γ-dependent and also mediated by the NO, opioid, and dopamine D 2 pathways. Losartan may be useful for IBS treatment.
K E Y W O R D Sangiotensin II type 1 receptor, gut barrier, irritable bowel syndrome, lipopolysaccharide, visceral sensation
“…20 Previous studies have demonstrated that stress increased CRF expression both in the brain and the intestine, 25,26 and CRF receptor antagonism both in the brain and in the periphery reversed visceral hypersensitivity induced by stress. 13,27 Another study examining the role of DNA methylation in visceral hypersensitivity showed that chronic water avoidance stress induced DNA methylation of the GR promoter and reduced its mRNA and protein expression in the dorsal root ganglia neurons innervating the pelvic viscera. 19 Chronic water avoidance stress also induced DNA methylation of the antinociceptive cannabinoid receptor 1 promoter and downregulated its expression, which may contribute to stress-induced visceral pain.…”
Abdominal pain is associated with many gastrointestinal dysfunctions, such as irritable bowel syndrome (IBS), functional dyspepsia, and inflammatory bowel disease (IBD). Visceral hypersensitivity is a key reason for development of abdominal pain that presents in these gastrointestinal disorders/diseases. The pathogenesis of visceral hypersensitivity is complex and still far from being fully understood. In animal studies, visceral hypersensitivity has been linked to several early-life adverse (ELA) events. In humans, IBD, functional dyspepsia, and IBS can have adult onset, though the adverse events that lead to visceral hypersensitivity are largely uncharacterized. In this issue of the journal, Aguirre et al. report the interesting finding that epigenetics underlies the effects of ELA events on visceral hypersensitivity. This mini-review examines models of ELA events leading to visceral hypersensitivity and the potential role of epigenetics, as reported by Aguirre et al. and others.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.